BRCA1 and breast cancer: Regarding clinical trials for breast cancer, the OlampiAD phase III study (NCT02000622) demonstrates that olaparib significantly prolongs PFS in patients with metastatic breast cancer and a germline BRCA1/2 mutation compared to standard therapy [30].